{"id":"https://openalex.org/W2021916539","doi":"https://doi.org/10.1097/00004714-198904000-00006","title":"Naloxone Suppresses Buprenorphine Stimulation of Plasma Prolactin","display_name":"Naloxone Suppresses Buprenorphine Stimulation of Plasma Prolactin","alternate_titles":[],"publication_year":1989,"publication_date":"1989-04-01","ids":{"openalex":"https://openalex.org/W2021916539","doi":"https://doi.org/10.1097/00004714-198904000-00006","mag":"2021916539","pmid":"https://pubmed.ncbi.nlm.nih.gov/2723127"},"language":"en","primary_location":{"id":"doi:10.1097/00004714-198904000-00006","doi":"https://doi.org/10.1097/00004714-198904000-00006","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004714-198904000-00006","pdf_url":null,"source":{"id":"https://openalex.org/S76849566","display_name":"Journal of Clinical Psychopharmacology","issn_l":"0271-0749","issn":["0271-0749","1533-712X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Psychopharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2021916539"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108552073","display_name":"Jack H. Mendelson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801148111","display_name":"McLean Hospital","ror":"https://ror.org/01kta7d96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801148111"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"JACK H. MENDELSON","raw_affiliation_strings":["Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts 02178","Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts 02178","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I2801148111"]},{"raw_affiliation_string":"Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I2801148111"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111605325","display_name":"Nancy K. Mello","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801148111","display_name":"McLean Hospital","ror":"https://ror.org/01kta7d96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801148111"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"NANCY K. MELLO","raw_affiliation_strings":["Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I2801148111"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005330893","display_name":"SIEW KOON TEOH","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]},{"id":"https://openalex.org/I2801148111","display_name":"McLean Hospital","ror":"https://ror.org/01kta7d96","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801148111"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"SIEW K. TEOH","raw_affiliation_strings":["Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, Massachusetts","institution_ids":["https://openalex.org/I136199984","https://openalex.org/I2801148111"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112762648","display_name":"John G. Lloyd-Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268051","display_name":"Reckitt Benckiser Health Limited (United Kingdom)","ror":"https://ror.org/05jqjhm27","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268051"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"JOHN G. LLOYD-JONES","raw_affiliation_strings":["Pharmaceutical Division, Reckitt and Colman, Ltd., England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Division, Reckitt and Colman, Ltd., England","institution_ids":["https://openalex.org/I4405268051"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110888758","display_name":"John M. Clifford","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268051","display_name":"Reckitt Benckiser Health Limited (United Kingdom)","ror":"https://ror.org/05jqjhm27","country_code":"GB","type":"company","lineage":["https://openalex.org/I4405268051"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"JOHN M. CLIFFORD","raw_affiliation_strings":["Pharmaceutical Division, Reckitt and Colman, Ltd., England"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical Division, Reckitt and Colman, Ltd., England","institution_ids":["https://openalex.org/I4405268051"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":94},"biblio":{"volume":"9","issue":"2","first_page":"105","last_page":"109"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.6973000168800354,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.6973000168800354,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10576","display_name":"Opioid Use Disorder Treatment","score":0.21559999883174896,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11199","display_name":"Pain Management and Opioid Use","score":0.016300000250339508,"subfield":{"id":"https://openalex.org/subfields/2703","display_name":"Anesthesiology and Pain Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/buprenorphine","display_name":"buprenorphine","score":0.9750000238418579},{"id":"https://openalex.org/keywords/naloxone","display_name":"naloxone","score":1.0},{"id":"https://openalex.org/keywords/prolactin","display_name":"prolactin","score":0.8429999947547913},{"id":"https://openalex.org/keywords/opioid-agonists","display_name":"opioid agonists","score":0.7820000052452087},{"id":"https://openalex.org/keywords/opioid-antagonists","display_name":"opioid antagonists","score":0.6610000133514404},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.6539999842643738},{"id":"https://openalex.org/keywords/abuse-potential","display_name":"abuse liability","score":0.7900000214576721},{"id":"https://openalex.org/keywords/opiate-abuse","display_name":"opiate abuse","score":0.7139999866485596},{"id":"https://openalex.org/keywords/parenteral-administration","display_name":"parenteral administration","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C2778949969","wikidata":"https://www.wikidata.org/wiki/Q407721","display_name":"Buprenorphine","level":4,"score":0.8286020755767822},{"id":"https://openalex.org/C2779064019","wikidata":"https://www.wikidata.org/wiki/Q66590068","display_name":"Prolactin","level":3,"score":0.8122444748878479},{"id":"https://openalex.org/C2778750930","wikidata":"https://www.wikidata.org/wiki/Q4540629","display_name":"(+)-Naloxone","level":4,"score":0.7482842206954956},{"id":"https://openalex.org/C24998067","wikidata":"https://www.wikidata.org/wiki/Q4114622","display_name":"Stimulation","level":2,"score":0.6864418983459473},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4943885803222656},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.48776036500930786},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.37083375453948975},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3624383807182312},{"id":"https://openalex.org/C2781063702","wikidata":"https://www.wikidata.org/wiki/Q427523","display_name":"Opioid","level":3,"score":0.3436402380466461},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3219769597053528},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.15967023372650146},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.043410301208496094}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002047","descriptor_name":"Buprenorphine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D009270","descriptor_name":"Naloxone","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011388","descriptor_name":"Prolactin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/00004714-198904000-00006","doi":"https://doi.org/10.1097/00004714-198904000-00006","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00004714-198904000-00006","pdf_url":null,"source":{"id":"https://openalex.org/S76849566","display_name":"Journal of Clinical Psychopharmacology","issn_l":"0271-0749","issn":["0271-0749","1533-712X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:2723127","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2723127","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical psychopharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G636800700","display_name":null,"funder_award_id":"DA 00064","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G6438016707","display_name":"POLYDRUG ABUSE IN WOMEN","funder_award_id":"P50DA004059","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G749051795","display_name":null,"funder_award_id":"DA00101","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2061341590","https://openalex.org/W2414333239","https://openalex.org/W1893489617","https://openalex.org/W2089382770","https://openalex.org/W2176110163","https://openalex.org/W2041138114","https://openalex.org/W2005551488","https://openalex.org/W1990603943","https://openalex.org/W2324977002","https://openalex.org/W2594014892"],"abstract_inverted_index":{"The":[0],"effects":[1],"of":[2,8,26,37,58,62,79,93,112,137,145,163,168,174,197,207,228,246],"parenterally-administered":[3],"buprenorphine":[4,39,45,63,140,152,183,208,238],"and":[5,30,42,48,66,82,86,141,149,195,220],"simultaneous":[6,34],"injection":[7,61,144],"naloxone":[9,113,148,175,193,235],"was":[10,19,97,114],"evaluated":[11],"in":[12,69,73,155,200],"six":[13,22],"healthy":[14],"adult":[15],"males.":[16],"Each":[17],"subject":[18],"studied":[20],"on":[21],"occasions,":[23],"an":[24,70],"average":[25,71],"10":[27,81],"days":[28],"apart,":[29],"received":[31],"either":[32],"two":[33],"intramuscular":[35],"injections":[36],"saline,":[38,43],"0.3":[40,46,53,64,118,138,150,169,184,209],"mg":[41,47,57,65,111,119,139,147,151,170,173],"or":[44,55,171],"0.6":[49,110],"mg,":[50,52,54],"0.45":[51,146],"0.15":[56,172],"naloxone.":[59],"Simultaneous":[60,143],"saline":[67],"resulted":[68,154],"increase":[72,199],"plasma":[74,94,122,201],"prolactin":[75,95,103,123,133,165,179,202,212],"above":[76],"baseline":[77],"levels":[78,96,124,203],"approximately":[80],"25":[83],"ng/ml,":[84],"30":[85],"55":[87],"minutes":[88],"after":[89,135,216],"injection.":[90],"Buprenorphine-induced":[91],"stimulation":[92,180,213],"statistically":[98],"significantly":[99,126],"greater":[100],"than":[101,107,130,132,161],"basal":[102],"values":[104,134],"(p":[105,128,159],"less":[106,129,160],"0.01).":[108],"When":[109],"simultaneously":[115],"injected":[116],"with":[117,224,232],"buprenorphine,":[120],"peak":[121],"were":[125],"lower":[127],"0.05)":[131,162],"administration":[136,206,219],"saline.":[142],"also":[153],"a":[156,189],"significant":[157],"attenuation":[158],"buprenorphine-stimulated":[164],"levels.":[166],"Injection":[167],"did":[176],"not":[177],"inhibit":[178],"produced":[181,204],"by":[182,205],"mg.":[185,210],"These":[186],"findings":[187],"demonstrate":[188],"dose-effect":[190],"relationship":[191],"between":[192],"concentration":[194],"suppression":[196],"the":[198,225,243],"As":[211],"occurs":[214],"shortly":[215],"opioid":[217],"agonist":[218],"is":[221],"temporally":[222],"concordant":[223],"rapid":[226],"induction":[227],"pharmacologic":[229],"reinforcement":[230],"associated":[231],"opiate":[233],"abuse,":[234],"added":[236],"to":[237],"parenteral":[239],"preparations":[240],"may":[241],"reduce":[242],"abuse":[244],"potential":[245],"buprenorphine.":[247]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2021916539","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}
